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A B S T R A C T
The influence of drug-target binding kinetics on target occupancy can be influenced by drug distribution and
diffusion around the target, often referred to as “rebinding” or “diffusion-limited binding”. This gives rise to a
decreased decline of the drug-target complex concentration as a result of a locally higher drug concentration that
arises around the target, which leads to prolonged target exposure to the drug. This phenomenon has been
approximated by the steady-state approximation, assuming a steady-state concentration around the target.
Recently, a rate-limiting step approximation of drug distribution and drug-target binding has been published.
However, a comparison between both approaches has not been made so far.
In this study, the rate-limiting step approximation has been rewritten into the same mathematical format as the
steady-state approximation in order to compare the performance of both approaches for the investigation of the
influence of drug-target binding kinetics on target occupancy.
While both approximations clearly indicated the importance of kon and high target concentrations, it was
shown that the rate-limiting step approximation is more accurate than the steady-state approximation, especially
when dissociation is fast compared to association and distribution out of the binding compartment.
It is therefore concluded that the new rate-limiting step approximation is to be preferred for assessing the
influence of binding kinetics on local target site concentrations and target occupancy.
1. Introduction
Although drug-target binding kinetics (the association and dissocia-
tion rate constants) is an important determinant of the kinetics of drug
action (Copeland et al., 2006; Yassen et al., 2007; Johnson et al., 2011;
Dahl and Akerud, 2013), its role can be influenced by rebinding or
diffusion-limited binding (Vauquelin and Charlton, 2010; de Witte
et al., 2016; Vauquelin, 2016). The term rebinding has been introduced
to describe the result of a (micro-)environment around the target site
which is not in instantaneous equilibrium with the plasma or target
tissue, and where a concentration difference between target site and
plasma or target tissue concentrations can be enhanced by drug-target
binding. This local target site concentration can thus induce a delay in
both drug-target association and dissociation and should therefore be
considered in the analysis and prediction of the relationship between
drug-target binding kinetics and target occupancy. This is especially
important when in vitro values for drug-target binding are used to
explain or predict in vivo target occupancy and effect.
The local concentration that drives rebinding has been approached
historically from different perspectives. The biophysical approach started
by describing diffusion around clustered receptors on a spherical or
planar surface, which was subsequently discretized by dividing the space
surrounding the receptor into the target vicinity and the bulk solution
(Goldstein and Dembo, 1995; Coombs and Goldstein, 2004). The
pharmacological approach started from in vitro/in vivo observations of
target binding that could not be explained by drug-target binding from
bulk/tissue concentrations, which was solved by assuming the existence
of a micro-compartment surrounding the target (De Meyts, 1976; Perry
et al., 1980; Frost and Wagner, 1984). The effect compartment model is a
less mechanistic and more general approach that is often used in PKPD
modelling to explain a delay between drug concentrations and drug
effect. In this approach, the drug concentrations in a hypothetical
compartment drive the drug effect. The effect compartment model is
most often combined with the assumption of fast target binding in the
effect compartment (resulting in a “Emax model”) (Francheteau et al.,
1993; Cleton et al., 1999; Nolan et al., 2006; Groenendaal et al., 2008),
although binding kinetics have also been incorporated in the effect
compartment model (Yassen et al., 2005; Äbelö et al., 2006).
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The mathematical models that have been proposed from the
different approaches as listed above share a similar compartmental
structure and give rise to similar equations. In these models, the
compartment in which binding takes place (in this paper referred to
as the binding compartment) represents the target site, which is the
(micro-) environment that surrounds the target (DeLisi, 1980; Perry
et al., 1980; Coombs and Goldstein, 2004; Yassen et al., 2005;
Vauquelin, 2010; Vauquelin and Charlton, 2010). An approximation
of these compartmental models has been derived previously by assum-
ing quasi steady-state in the binding compartment (DeLisi, 1980) and
has been used since for simulation studies (Vauquelin and Charlton,
2010; Vauquelin, 2016). We will refer to this approximation as the
steady-state approximation. A recent comparison between the steady-state
approximation of rebinding and the effect compartment model (which
has the same mathematical structure as the full two-compartment
model from which the steady-state approximation is derived) indicated
that the steady-state approximation is not capturing the behavior of the
effect compartment model for fast dissociating ligands (Vauquelin,
2016).
A recently published approximation for describing target binding
from a local (tissue) compartment, assumed that the overall decline of
target occupancy is most influenced by the slowest process (the rate-
limiting step) (de Witte et al., 2016). We will refer to this approxima-
tion as the rate-limiting step approximation.
The rate-limiting step approximation has not yet been compared with
the steady-state approximation as described by deLisi (1980). In this
study, we use the rate limiting step approximation and the steady-state
approximation of drug distribution and drug-target binding and compare
their ability to capture the behavior of the original compartmental
model, from which both models are derived.
2. Methods
To allow comparison of the steady-state approximation and the rate-
limiting step approximation of drug-target binding and drug distribution
as proposed here, both approximations should be written in the same
mathematical format. In Appendix A, the steady-state rebinding








In Eq. (1), df1 is the delay factor for Model 3 that is multiplied with
koff and kon to account for the influence of the local concentration, kout is
the first-order distribution or diffusion rate constant from the micro
compartment into plasma, kon is the second-order association rate
constant and N is the unbound target concentration.
In Appendix B, our rate-limiting step formula for rebinding is
derived from our previously published approximation of target binding,
tissue distribution and plasma elimination, resulting in Eq. (2).
df k BF
k k BF k N
= ⋅(1 − )





In Eq. (2), df2 is the delay factor for Model 4, the additional
parameter BF is the fraction of target that is bound to the drug and koff is
the first-order dissociation rate constant. It should be noted that kout is
used to replace the drug distribution rate constant that has been called
k− or just k in the biophysical approach, kout in the mechanistic
pharmacological approach and keo in the non-mechanistic PKPD
modelling approach.
Our rate-limiting step approximation of target binding was intended to
approximate the duration of target occupancy after its maximal value
and is thus applicable to calculate the delay factor for koff. However,
both koff and kon need to be multiplied with the same delay factor to
ensure that rebinding does not affect equilibrium target occupancy.
Multiplying kon and koff with the same factor is also common practice in
previous rebinding studies (Coombs and Goldstein, 2004; Vauquelin,
2016).
To assess the performance of the rate-limiting step approximation and
to compare this with the recently published evaluation of the steady-
state approximation, four different mathematical models were com-
pared.
Model 1 (Fig. 1) is the full compartmental model that consists of a
depot compartment from which absorption into plasma occurs, a
central compartment representing the blood, a binding compartment
Fig. 1. Schematic representation of all model structures that are used for simulations. Model 1 and Model 2 share a similar model structure, as depicted in the left panels. Model 3 and
Model 4 share the model structure as depicted in the right panels. Dashed arrows indicate the absence of mass transfer between compartments. The binding compartment in Model 1 and
Model 2 is assumed to be very small and the mass transfer between the Central and Binding compartment is ignored. This allows the direct modelling of the concentrations in the Binding
compartment and the assumption that kout equals kin.
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in which binding occurs and a ligand-receptor compartment that
represents ligand in the target-bound state. Since rebinding is often
hypothesized to occur from a small “micro-compartment”, the mass
transfer from plasma to this compartment was assumed to be negligible
and was excluded from the model equations. However, since rebinding
can result in accumulation or depletion of ligand in the binding
compartment, mass transfer was incorporated in the model equations
describing the concentration in the binding compartment.
Model 2 (Fig. 1) is equal to Model 1, except that it does not take into
account mass transfer between the binding compartment and the target-
bound compartment. This model was required for comparison with the
previous publication on the performance of the steady-state rebinding
formula in which Model 2 was compared to Model 3 (Vauquelin, 2016).
Model 3 (Fig. 1) encompasses an absorption and a central compart-
ment in the same way as Model 1, but drug-target binding is now driven
by the plasma concentrations. Both kon and koff are multiplied by the
delay factor, according to the steady-state approximation (Eq. (1)).
Model 4 (Fig. 1) is the same as Model 3, but kon and koff are now
multiplied by the delay factor according to the newly derived rate-
limiting step approximation (Eq. (2)).
As Model 1 is the original compartmental model that is approxi-
mated by Model 3 and Model 4, we can assess the performance of Model
3 and Model 4 by comparing the simulation outcomes of these models
to the outcome of Model 1. More similarity to Model 1 means a more
accurate approximation. Model 2 is included for comparison with the
recent publication of Vauquelin (2016), in which Model 2 was
compared to Model 3. Also, the parameter values for kon, koff, kout, kel
and ka were set to the same values as for the simulations in the study of
Vauquelin (2016). In contrast to the publication of Vauquelin, the delay
factor is calculated from Eqs. (1) and (2), where kout is used both for
simulation of distribution to the binding compartment and for calcula-
tion of the delay factor. The total target concentration was chosen to
yield similar results as in the recent publication of Vauquelin (2016).
The differential equations for all models are given in Appendix C.
The initial concentration in the absorption compartment was 15·KD in
all simulations. The differential equations were solved by using the
lsoda solving method in the deSolve package in R, version
3.3.1(Soetaert et al., 2010; R Core Team, 2013).
3. Results
The only differences between Eqs. (1) and (2) are the addition of koff
in the denominator and the correction for the influence of target
saturation in the factor (1 − BF). Since koff + kout · (1 − BF) + kon · N
reduces to kout · (1 − BF) + kon · N if koff ≪ kout · (1 − BF) + kon · N,
Eqs. (1) and (2) only give similar results for the delay factor df if koff
is relatively small compared to kout · (1 − BF) or kon · N. This corre-
sponds to the steady-state approximation that is used to derive Eq. (1),
which assumes that the concentration in the binding compartment
adapts quickly to the surrounding concentrations. This requires that the
rate at which the drug is distributed out of the binding compartment
(determined by kout · (1 − BF) and kon · N) is relatively large compared
Fig. 2. Comparative simulations of target occupancy (TO) over time for the Models 1–4. Unless otherwise indicated above the panels, the parameter values remain the same as for panel
A: kout = 10 (solid line), 0.0047 (dashed line), 0.0005 (dotted line) or 0.000087 (dash-dotted line) min−1. koff = 0.0069 min−1, kon = 1·107 M−1·min−1, [Rtot] = 1 nM,
ka = 0.0115 min−1 and kel = 0.00575 min−1. The different grey tones are used for visual distinction of the lines.
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to the rate at which drug is distributed into the binding compartment
(determined by koff). It should be noted that the influence of the
saturation factor (1 − BF) only has a major influence for high values of
target occupancy.
The performance of our rate-limiting step approximation has been
visualized in Figs. 2 and 3. Fig. 2A demonstrates that both approxima-
tions (steady-state: Model 3 and rate-limiting step: Model 4) produce
similar results as Model 1, although Model 4 seems to approximate
Model 1 a bit better than Model 3 does. In Fig. 2B, the difference
between Model 3 and Model 4 is clearly demonstrated for the
simulations with the lowest values of kout and Model 4 performs much
better for the parameter values that were used for Fig. 2B (i.e. high koff,
low affinity and average receptor concentration). The mismatch
between Model 3 and Model 1 in Fig. 2B is not only the result of the
high dissociation rate constant: if the target concentration is set to 1 pM
instead of 1 nM, a similar mismatch as in Fig. 2B is observed, as
demonstrated in Fig. 2C. As can be derived from Eqs. (1) and (2), the
same effect is observed when the kon value is lowered instead of the
target concentration (data not shown). Similarly, the mismatch be-
tween Model 3 and Model 1 in Fig. 2B can be almost completely
reversed by a thousand-fold increase in the target concentration or the
kon (Fig. 2D).
The performance of our rate-limiting step approximation of rebinding
was also investigated in the context in which rebinding formulas are
frequently applied: in simulations of the influence of koff on target
occupancy. Fig. 3A demonstrates that the influence of koff is much
better approximated by Model 4 than by Model 3. Although Model 4
also shows a mismatch in the increase rate of target occupancy for the
lowest koff values, the duration of target occupancy and the influence of
koff thereon resemble Model 1 closely (note the increase in the
simulation duration).
For a more typical drug treatment situation, with nanomolar drug-
target affinity and target concentration and a moderate delay in
distribution from plasma to the binding site, both Model 3 and Model
4 produce comparable results with Model 1, as illustrated in Fig. 3B.
The result of incorporating a correction for target saturation in our rate-
limiting step approximation is illustrated in Fig. 3C and D: While for
Fig. 3C Model 3 and Model 4 result in similar simulations, an increased
dose results in a mismatch between Model 3 and Model 1, which is not
observed for Model 4.
4. Discussion
The rate-limiting step approximation for drug distribution and drug-
target binding that we propose here on basis of our previous publication
differs significantly from the steady-state approximation when the
dissociation rate constant (koff) is high, compared to the distribution
rate constant (kout) and the product of the association rate constant and
the unbound target concentration (kon · N). This difference results in an
improved approximation of the original compartmental model (Model
1), from which both approximations are derived.
The improved robustness of the rate-limiting step approximation
Fig. 3. Comparative simulations of target occupancy (TO) over time for the different models. Unless otherwise indicated above the panels, the parameter values remain the same as for
panel A: koff = 0.1 (solid line), 0.01 (dashed line), 0.001 (dotted line) or 0.0001 (dash-dotted line) min−1. kout = 0.00006 min−1, KD = 1·10−7 M, [Rtot] = 10 nM, ka = 0.0115 min−1,
kel = 0.00575 min−1 and C0 (the initial concentration) = 15·KD. The different grey tones are used for visual distinction of the lines.
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compared to the steady-state approximation that we demonstrated here,
yields a mathematically reliable simulation of the influence of kon and
koff for a wider range of pharmacological situations. Moreover, our new
approximation can help to understand the role of the relevant
parameters and to interpret the observed influence of rebinding from
in vivo, in vitro or in silico data. For example, the steady-state approxima-
tion results in a decline of target occupancy that is linearly related to koff
as long as the drug elimination from plasma is not rate-limiting (Eq.
(1)). This is not in line with the intuitive thinking that the distribution/
diffusion out of the target vicinity could also be determining the
decrease of target occupancy, which would make koff less influential.
With our rate-limiting step approximation, this intuitive thought is
confirmed and the influence of koff on the decline rate of target
occupancy decreases when koff becomes relatively large. Also, a correct
approximation of binding and distribution is essential if this approx-
imation is used to discriminate between various mechanisms that can
explain the duration of drug action or target occupancy.
While the rate-limiting step approximation as presented here is a more
robust approximation than the steady-state approximation, the difference
between these two approximations is most significant when the extent
of the influence of drug distribution is low (since the product of target
concentration and kon has to be relatively small). We do not provide a
rigorous mathematical proof here that the rate-limiting step approxima-
tion is better than the steady-state approximation. However, the deter-
mining equations and the simulations make clear that the rate-limiting
step approximation can be significantly different and more accurate for
conditions with limited rebinding, slow distribution out of the binding
compartment and relatively fast dissociation. An approximation of the
full rebinding model, such as the two approximations discussed here, is
not required for simulations or model fitting of drug distribution and
drug-target binding, since the full compartmental model (Model 1) can
be used. However, the previous use of the steady-state approximation
demonstrates the value of the rate-limiting step approximation for
investigations in the role of drug-target binding kinetics and rebinding.
In conclusion, the rate-limiting step approximation provides an
improved approximation of drug-target binding and drug distribution
which can be used as an alternative for the existing steady-state
approximation. Using the rate-limiting step approximation as presented
here is especially important when dissociation is fast compared to
association and distribution out of the binding compartment.
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Appendices
Appendix A: rewriting the steady-state approximation of rebinding
In the steady-state approximation of rebinding, both kon and koff are multiplied with the delay factor df1 that is defined in Eq. (A.1), where all
parameters are defined as explained in methods (Vauquelin, 2016):
df = 1




Eq. (A.1) can be rewritten as Eq. (A.2), which equals Eq. (A.3), which provides Eq. (1) of the main text.
df = 1k k N
k









Appendix B: derivation of the rate-limiting step approximation of target binding and drug distribution
For the rate-limiting step approximation, our previously published approximation of pharmacokinetics and target binding was used as the starting
point (de Witte et al., 2016). From this publication, Eq. (S35) is the most relevant which is given as Eq. (B.1) here. In Eq. (B.1), λTO(BF) is the
fractional decrease in target occupancy, as a function of the target fraction bound (BF). λelTO(BF) is the value that λTO(BF) would have if the
elimination would be rate limiting and thus determining the decrease of target occupancy. λoutTO(BF) is the value that λTO(BF) would have if drug
distribution from the binding compartment to plasma would be rate limiting. λTO(BF) equals the reverse rate constant koff ·df from Eqs. (1) and (2) if
there would be no drug in plasma, i.e. if the elimination rate would be extremely high. Such a high elimination rate can be assumed for Eqs. (1) and
(2), since these equations are meant for models that simulate plasma concentrations separately. Assuming an extremely high elimination rate
constant leads to an extremely high value of λelTO(BF), which reduces Eqs. (B.1) and (B.2).
λ BF( ) = 1
+ +
TO






elTO outTO off (B.1)








Since λoutTO(BF) is given by Eq. (B.3) according to our previous publication (Eq. (S33)), Eq. (B.2) equals Eq. (B.4), which can be rewritten as Eq.
(B.5).
λ BF k BF
R
( ) = ∙(1 − )
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Eq. (B.5) can be rewritten as Eq. (B.6) by realizing that KD equals the ratio of koff to kon and by multiplying each fraction by unity in such a way
that the denominators become equal and the two fractions can be summed as in Eq. (B.7). Eq. (B.7) equals Eq. (B.8) and since [Rtot]·(1 − BF) is equal
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out off
off tot on out (B.8)
Appendix C: differential equations of the four different models as used for the simulations
The concentrations in the depot and the central compartment were modeled in the same way for all four models according to Eqs. (C.1) and (C.2),
respectively. In these equations, [DEP] is the drug concentration in the depot compartment, [C] is the drug concentration in the central
compartment, ka is the first-order absorption rate constant and kel is the first-order elimination rate constant.
d DEP
dt
k DEP[ ] = − ∙[ ]a (C.1)
d C
dt
k DEP k C[ ] = ∙[ ] − ∙[ ]a el (C.2)
The concentration in the binding compartment is only explicitly simulated in Model 1 and Model 2 according to Eqs. (C.3) and (C.4), respectively.
Here, [B] denotes the drug concentration in the binding compartment, [N] denotes the unbound target concentration (which is calculated by
assuming the total target concentration is constant), [LR] denotes the drug that is bound to the target, kout is the first-order distribution constant








k C B[ ] = ∙([ ] − [ ])out (C.4)
The concentration of the target-bound drug is calculated identically for Model 1 and Model 2 according to Eq. (C.5):
Model 1, Model 2:
d LR
dt
k B N k LR[ ] = ∙[ ]∙[ ] − ∙[ ]on off (C.5)
For Model 3 and Model 4 the target bound drug is calculated according to Eqs. (C.6) and (C.7), where BF denotes the fraction of the target that is




k C N k LR k
k k N






k C N k LR k BF
k k BF k N
[ ] = ( ∙[ ]∙[ ] − ∙[ ])∙
∙(1 − )
+ ∙(1 − ) + ∙on off
out
off out on (C.7)
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